(HealthDay)—The combination of low muscle mass (LMM) and low muscle density (LMD) is associated with shorter survival in patients with diffuse large B-cell lymphoma (DLBCL), according to a study published online March 13 ...
Mar 19, 2020
0
2
A new category of immunotherapies called checkpoint inhibitors that has been highly effective against many different cancers appears safe to use in patients with both advanced malignancies and HIV, a population excluded from ...
Nov 7, 2017
0
9
A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein. However, a research team, led by investigators at Weill Cornell ...
May 13, 2013
0
0
An important regulator that controls the ability of tumour cells to hide from the immune system in lymphoma patients, making them unlikely to respond to standard treatment, has been discovered by scientists at the University ...
Oct 30, 2015
0
10
In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first ...
Dec 6, 2014
0
0
Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a "surprisingly high" response ...
Dec 11, 2023
0
0
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell – DLBCL ...
Dec 10, 2012
0
0
A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at risk for second cancers, ...
Jun 26, 2012
0
0
Chimeric antigen receptor T-cell therapy, or CAR T, has dramatically improved the treatment of certain blood cancers. Initially approved for patients who had failed multiple lines of therapy, clinical trials have shown CAR ...
Jan 17, 2024
0
36
Patients living with an aggressive form of lymphoma in Scotland will not get routine access to a new immunotherapy treatment after it was rejected for use on the NHS.
Mar 14, 2019
0
3
